Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + docetaxel + cisplatin + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen, often referred to as mDCF plus trastuzumab, is a chemo-immunotherapy protocol evaluated by Memorial Sloan Kettering Cancer Center for the treatment of HER2-positive unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. The regimen consists of the monoclonal antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2), combined with a modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy backbone. The modification (mDCF) is designed to reduce the significant toxicities associated with the standard DCF regimen while maintaining therapeutic efficacy. Trastuzumab works by binding to the extracellular domain of HER2, inhibiting downstream proliferative signaling and inducing antibody-dependent cellular cytotoxicity (ADCC). The chemotherapy components provide synergistic cytotoxic effects by disrupting microtubule function (docetaxel), inducing DNA cross-linking (cisplatin), and inhibiting thymidylate synthase (fluorouracil, modulated by leucovorin).
- Brand names
- HerceptinTaxoterePlatinolAdrucil
- Other names
- mDCF + trastuzumabmodified DCF plus trastuzumabTrastuzumab plus modified Docetaxel, Cisplatin, and Fluorouracil
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + docetaxel + cisplatin + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + docetaxel + cisplatin + fluorouracil + leucovorin.